In accordance with prescribing-information recommendations, paliperidone palpitate was changed from a monthly dose to a three-monthly dose in the treatment of veterans with schizophrenia. This study describes and compares treatment patterns, resource usage, and expenditures before and after the transition. Utilizing information from the Veterans Health Administration's electronic health records, this retrospective, longitudinal study VHA. Veterans were included if they were 18 years of age or older, had received one prescription for PP3M, had been enrolled in VHA benefits for 24 months prior to switching to PP3M, had been diagnosed with schizophrenia once, and had been switched to PP3M in accordance with prescribing-information guidelines. Operationalized as no 45-day break in PP1M treatment over the four months before PP3M.
Published Date: 2022-08-31; Received Date: 2022-08-01
